Company: MBIO
Filing Date: 2025-04-04
Form Type: POS AM
Source: 0001104659-25-032236
Chunk: 5

Company: MUSTANG BIO, INC.
Filing Date: 2025-04-04
Form: POS AM
Chunk 5
---
 and does not contain all of the information you should consider in making your investment decision. Before investing in our common stock, you should carefully read the entire prospectus and the documents incorporated by reference herein, including the risks of investing in our securities discussed under the heading “Risk Factors” and “Special Note Regarding Forward-Looking Statements” in this prospectus and under similar captions in documents incorporated by reference into this prospectus. You should also carefully read our financial statements and the exhibits to the registration statement of which this prospectus forms a part. Unless the context otherwise requires, the terms “Mustang” “Mustang Bio” “the Company,” “we,” “us,” “our” and similar references in this prospectus refer to Mustang Bio, Inc., the registrant on the cover page of the registration statement of which this prospectus forms a part.

Our Business

Overview and Product Candidate Development

We are a clinical-stage biopharmaceutical company
focused on translating today’s medical breakthroughs into potential cures for difficult-to-treat cancers. We aim to acquire rights
to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development
and eventually either out-licensing or bringing the technologies to market.

Our pipeline is currently focused in two core
areas: CAR T therapies for hematologic malignancies and CAR T therapies for solid tumors. For these therapies we have partnered with world
class research institutions, including the City of Hope National Medical Center, Fred Hutchinson Cancer Center, and Nationwide Children’s
Hospital.

Corporate Information

We are a majority-controlled subsidiary of Fortress
Biotech, Inc. We were incorporated under the laws of the State of Delaware on March 13, 2015. Our principal executive offices
are located at 95 Sawyer Road, Suite 110, Waltham, Massachusetts 02453, and our telephone number is 781-652-4500. We maintain a website
on the Internet at www.mustangbio.com and our e-mail address is info@mustangbio.com. Information on our website, or any other website,
is not incorporated by reference in this prospectus. We have included our website address in this prospectus solely as an inactive textual
reference.

Implications of Being a Smaller Reporting Company

We are a “smaller reporting company”
as defined in the Securities Exchange Act of 1934, as amended (the “Exchange Act”). We may take advantage of certain of the
scaled disclosures available to smaller reporting companies and will